XML 52 R31.htm IDEA: XBRL DOCUMENT v3.22.1
Organization and Description of the Business (Details)
$ in Thousands, € in Millions
1 Months Ended 12 Months Ended
Jul. 30, 2021
USD ($)
Jul. 30, 2021
EUR (€)
May 11, 2021
USD ($)
tranche
Sep. 23, 2020
shares
Dec. 31, 2020
USD ($)
shares
Sep. 30, 2020
USD ($)
Jun. 30, 2020
USD ($)
shares
Dec. 31, 2021
USD ($)
shares
Dec. 31, 2021
EUR (€)
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2021
EUR (€)
shares
Liquidity                      
Net loss               $ 98,776   $ 67,475  
Accumulated deficit         $ 311,929     410,705   $ 311,929  
Refundable portion of upfront payment               $ 21,233      
Reverse stock split ratio       0.25              
Common stock, shares authorized | shares       150,000,000 150,000,000     150,000,000   150,000,000 150,000,000
Oaktree Capital Management LP Credit Agreement                      
Liquidity                      
Term of loan facility     5 years                
Maximum borrowing capacity available under the credit agreement     $ 125,000                
Number of tranches | tranche     5                
Additional borrowing capacity available, subject to certain milestone events     $ 80,000                
Oaktree Capital Management LP Credit Agreement | Funding of the tranche A- 2 term loans until the funding of the tranche B term loans                      
Liquidity                      
Minimum liquidity to be maintained     20,000         $ 20,000      
BARDA Contract                      
Liquidity                      
Maximum amount to be awarded under the contract           $ 51,000          
Contract base period           2 years          
Amount of funding to be provided during contract base period           $ 21,000          
Amount of additional funding to be provided following successful completion of clinical trial and preclinical studies in base period           30,000          
Cost sharing, amount           33,000          
Cost sharing, BARDA amount           $ 51,000          
Contract period-of-performance           5 years          
Collaboration Agreement with Orion                      
Liquidity                      
Upfront fee received $ 29,600 € 25.0             € 25.0    
R&D reimbursement and cash milestone payments to be received | €   € 97.0                  
Number of days from receipt of the final report, in which the collaboration agreement may be terminated 90 days 90 days                  
Percentage of upfront fee which must be refunded in the event of termination   75.00%                  
Refundable portion of upfront payment               21,200     € 18.8
Term Loan Tranche B | Oaktree Capital Management LP Credit Agreement                      
Liquidity                      
Additional borrowing capacity available, subject to certain milestone events     $ 30,000         $ 30,000      
Common Stock | Public Offering.                      
Liquidity                      
Issuance of common stock (in shares) | shares         5,000,000   4,600,000        
Proceeds from equity offerings, net of offering costs         $ 64,800   $ 43,000